Epigenetic silencing of cell cycle regulatory genes during 3-methylcholanthrene and diethylnitrosamine-induced multistep rat lung cancer

Molecular Carcinogenesis

Volumn 49, Issue 6, 2010, Pages 556-565

  Liu, Wen Bin ^a   Liu, Jin Yi ^a   Ao, Lin ^a   Zhou, Zi Yuan ^a   Zhou, Yan Hong ^a   Cui, Zhi Hong ^a   Cao, Jia ^a  

^a NONE

Author keywords

CDKN1B (p27); CDKN1C (p57); Cell cycle; DNA methylation; Lung cancer

Indexed keywords

3 METHYLCHOLANTHRENE; 5 AZA 2' DEOXYCYTIDINE; DIETHYLNITROSAMINE; PROTEIN P27; PROTEIN P57;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMA IN SITU; CDKN1B GENE; CDKN1C GENE; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE SEQUENCE; GENE SILENCING; LUNG CANCER; LUNG CARCINOGENESIS; MALE; METHYLATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TUMOR GENE;

ANIMALS; CARCINOMA; CELL CYCLE; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DIETHYLNITROSAMINE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LUNG NEOPLASMS; MALE; METHYLCHOLANTHRENE; PROMOTER REGIONS, GENETIC; RATS; RATS, WISTAR;

ANIMALIA; RATTUS;

EID: 77953894146     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20621     Document Type: Article

References (48)

1. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009;9:153-166.
2. Malumbres M. Cyclins and related kinases in cancer cells. J Buon 2007;12:S45-S52. (Pubitemid 350200861)
3. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-149. (Pubitemid 36808270)
4. Santamaria D, Ortega S. Cyclins and CDKs in development and cancer: Lessons from genetically modified mice. Front Biosci 2006;11:1164-1188. (Pubitemid 43253468)
5. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
6. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001;58:1907-1922.
7. Sherr CJ. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 2000;60:3689-3695.
8. Malumbres M, Barbacid M. To cycle or not to cycle: A critical decision in cancer. Nat Cancer Rev 2001;1:222-231. (Pubitemid 33741897)
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
10. Liu Z, Zhao J, Chen XF, et al. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer. Lung Cancer 2008;62:15-22.
11. Furonaka O, Takeshima Y, Awaya H, Ishida H, Kohno N, Inai K. Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 2004;54:549-555.
12. Toyooka S, Matsuo K, Gazdar AF. DNA methylation in lung cancer. N Engl J Med 2008;358:2513-2514.
13. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
14. Tian HS, Liu MQ, Gao WQ, Zuo RD, Xiong YY, Chen ZF. Induction of lung carcinoma by intralobar bronchial instillation of iodized oil in rats. Chin Med J 1984;97:36-40.
15. Liu WB, Liu JY, Cao J. Comparison of establishing rat model of lung squamous cell carcinoma by different anesthesia. Chin J Comp Med 2008;18:54-57.
16. Li HG, Liu MQ, Diao LM, et al. Microdissection and PCR-SSCP detected mutation and expression of p53 and K-ras gene in carcinogenesis and development of induced rat lung carcinoma. Chin J Pathol 2002;31:331-336.
17. Wang J, Chen HL, Zhu RQ, et al. Expression of apoptosis and proliferation related genes in carcinogenesis of lung squamous carcinoma in rats. Chin J Cancer 2003;22:471-476.
18. Liu WB, Liu JY, Ao L, et al. Dynamic changes in DNA methylation during multistep rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. Toxicol Lett 2009;189:5-13.
19. Tsujiuchi T, Masaoka T, Sugata E, et al. Hypermethylation of the Dal-1 gene in lung adenocarcinomas induced by N-nitrosobis(2-hydroxypropyl)amine in rats. Mol Carcinog 2007;46:819-823. (Pubitemid 47549768)
20. Shimizu K, Itsuzaki Y, Onishi M, Fujii H, Honoki K, Tsujiuchi T. Reduced expression of the Tslc1 gene and its aberrant DNA methylation in rat lung tumors. Biochem Biophys Res Commun 2006;347:358-362. (Pubitemid 44015684)
21. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-418. (Pubitemid 34164013)
22. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
23. Wang YC, Lin RK, Tan YH, Chen JT, Chen CY. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: An alternative pathway to non-small-cell lung cancer. J Clin Oncol 2005;23:154-164.
24. Ji W, Yang L, Yu L, et al. Epigenetic silencing of O6-methylguanine DNA methyltransferase gene in NiS-transformed cells. Carcinogenesis 2008;29:1267-1275.
25. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J, Belinsky SA. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 2008;68:9005-9014.
26. Bagnyukova TV, Tryndyak VP, Montgomery B, et al. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008;29:638-646.
27. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/CDK4. Nature 1993;366:704-707.
28. Yoshimoto K, Tanaka C, Yamada S, et al. Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary adenomas. Eur J Endocrinol 1997;136:74-80. (Pubitemid 27090683)
29. Kiyokawa H, Kineman RD, Manova-Todorova KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 1996;85:721-732. (Pubitemid 26181051)
30. Tsoli E, Gorgoulis VG, Zacharatos P, et al. Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas. Mol Med 2001;7:418-429.
31. Hayashi H, Ito T, Yazawa T, et al. Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma. J Pathol 2000;192:26-31.
32. Ponce-Castaneda MV, Lee MH, Latres E, et al. p27kip1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-1214.
33. Stegmaier K, Takeuchi S, Golub TR, Bohlander SK, Bartram CR, Koeffler HP. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res 1996;56:1413-1417. (Pubitemid 26080987)
34. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234. (Pubitemid 27064711)
35. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997;11:342-345. (Pubitemid 27120981)
36. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
37. Qian X, Jin L, Kulig E, Lloyd RV. DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 1998;153:1475-1482. (Pubitemid 28509904)
38. Lei PP, Zhang ZJ, Shen LJ, Li JY, Zou Q, Zhang HX. Expression and hypermethylation of p27 kip1 in hepatocarcinogenesis. World J Gastroenterol 2005;11:4587-4591. (Pubitemid 41150405)
39. Kibel AS, Christopher M, Faith DA, Bova GS, Goodfellow PJ, Isaacs WB. Methylation and mutational analysis of p27(kip1) in prostate carcinoma. Prostate 2001;48:248-253. (Pubitemid 32816550)
40. Zhang P, Liegeois N, Wong C, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-158.
41. Li JQ, Wu F, Usuki H, et al. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 2003;23:1537-1543.
42. Kikuchi T, Toyota M, Itoh F, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002;21:2741-2749.
43. Li Y, Nagai H, Ohno T, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002;100:2572-2577.
44. Shen L, Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101:4131-4136.
45. Kobatake T, Yano M, Toyooka S, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004;12:1087-1092.
46. Pateras IS, Apostolopoulou K, Koutsami M, et al. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in non small cell lung cancer. Int J Cancer 2006;119:2546-2556.
47. Sasaki M, Sugio K, Kuwabara Y, et al. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. Ann Nucl Med 2003;17:189-196.
48. Blanco D, Vicent S, Fraga MF, et al. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 2007;9:840-852.